Octapharma USA Expands FDA Approval for wilate® in Children
PARAMUS, N.J. | July 8, 2026 Octapharma USA has announced that the U.S. Food and Drug Administration (FDA) has...
Hemophilia A
Advertisement
Novo Nordisk Showcases New Hemophilia Data Featuring Denecimig at ISTH 2026
PLAINSBORO, N.J., and BAGSVÆRD, Denmark, June 26, 2026 Novo Nordisk announced it will present new clinical and scientific findings...
Novo Nordisk Reports Strong Phase 3 Results for Denecimig in Hemophilia A
PLAINSBORO, N.J. & BAGSVAERD, Denmark, April 29, 2026 Novo Nordisk has announced that its investigational therapy denecimig (Mim8) significantly...
Novo Nordisk Submits BLA for Mim8, Offering Flexible Hemophilia A Prophylaxis
Bagsværd, Denmark & Plainsboro, N.J., September 29, 2025 – Novo Nordisk has formally submitted a Biologics License Application (BLA)...
Advertisement
